Caroline Seymour

The addition of ipatasertib to paclitaxel failed to improve progression-free survival and objective response rates versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.

Hemigland high-intensity focused ultrasound ablation of the prostate was found to be a safe and effective primary treatment for men with localized prostate cancer, leading to continence preservation and suitable short-term disease control.

The open-label arm of the 3-part phase 3 SYMPATICO trial is evaluating the combination of ibrutinib and venetoclax in previously untreated patients with mantle cell lymphoma.

Sawsan Rashdan, MD, discusses the current treatment paradigm of patients with resectable and metastatic EGFR-mutant NSCLC.

Luciano J. Costa, MD, PhD, discusses emerging data regarding the use of BCMA-directed bispecific antibodies and antibody-drug conjugates in multiple myeloma.

The addition of enzalutamide to androgen deprivation therapy (ADT) led to maintained health-related quality of life and low symptom burden versus placebo and ADT in men with metastatic castration-sensitive prostate cancer.

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial, the importance of histologic stratification, and ongoing challenges in soft tissue sarcoma.

Benoit You, MD, PhD, discusses the need for novel and well-tolerated agents in chemotherapy-resistant gestational trophoblastic tumors and ongoing research efforts designed to bring avelumab to the forefront of the treatment paradigm.

Jacob S. Thomas, MD, discusses the pharmacodynamic profile of INT230-6 as well as preliminary safety and efficacy data with the agent in advanced solid tumors.

Katja Weisel, MD, explains the rationale for the GMMG-CONCEPT trial, details the key interim findings, and provides foresight on future milestones in the field of multiple myeloma.

Eleni Gavriilaki, MD, PhD, discusses the rationale for the lectin pathway as a therapeutic target in hematopoietic stem cell transplantation–associated thrombotic microangiopathy.

Tafasitamab has been added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

Ripretinib demonstrated promising antitumor activity and was found to be well tolerated in patients with refractory advanced gastrointestinal stromal tumor.

Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.

Tipifarnib demonstrated encouraging antitumor activity in patients with recurrent and metastatic head and neck cancer with high HRAS-mutant variant allele frequency, surpassing historical competitors in the second- or later-line settings.

Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.

Jordan D. Berlin, MD, discusses the importance of more data and more effective treatment regimens in metastatic pancreatic cancer, despite the number of treatment options currently available.

The interim futility review for the phase 2 HopES Sarcoma trial was positive and will continue to evaluate SM-88 for patients with Ewing sarcoma and other high-risk sarcomas.

Patients with a suspected or diagnosed myeloproliferative neoplasm should undergo targeted next-generation sequencing versus sequential or allele specific testing to reduce the risk of identifying a false driver mutation or an excluded diagnosis of MPN.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses immunotherapy, PARP inhibitors, and antibody-drug conjugates, which have become pillars of treatment in triple-negative breast cancer.

Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.

John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the risk of late recurrence in early breast cancer, current approaches to extended adjuvant endocrine therapy, and ongoing research evaluating assays aimed at capturing both the risk of late recurrence and benefit from extended endocrine therapy.

Vamsidhar Velcheti, MD, discusses the current and emerging treatment options for patients with ALK- and ROS1-positive non–small cell lung cancer.

Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Joshua K. Sabari, MD, discusses a number of immunotherapy regimens that have emerged in the frontline setting for patients with driver-negative advanced non–small cell lung cancer; however, for many patients, the decision comes down to pembrolizumab monotherapy or pembrolizumab in combination with platinum-doublet chemotherapy.

The administration of luteinizing hormone-releasing hormone agonists in patients with prostate cancer was significantly more delayed in clinical practice than in pivotal clinical trials.